The prevalence of symptoms of sensorimotor and autonomic neuropathy in Type 1 and Type 2 diabetic subjects

References 

1. Armstrong DG, Lavery LA, Vela SA, Quebedeaux TL, Fleischli JG. Choosing a practical screening instrument to identify patients at risk for diabetic foot ulceration. Archives of Internal Medicine. 1998;158:289–292
   • MEDLINE
   • CrossRef
2. Bax G, Fagherazzi C, Piarulli F, Nicolucci A, Fedele D. Reproducibility of Michigan Neuropathy Screening Instrument (MNSI). A comparison with tests using the vibratory and thermal perception thresholds. Diabetes Care. 1996;19:904–905
   • MEDLINE
3. Cameron NE, Cotter MA. Metabolic and vascular factors in the pathogenesis of diabetic neuropathy. Diabetes. 1997;46:S31–S37
4. Dyck PJ, Davies JL, Litchy WJ, O'Brien PC. Longitudinal assessment of diabetic polyneuropathy using a composite score in the Rochester Diabetic Neuropathy Study cohort. Neurology. 1997;49:229–239
   • MEDLINE
   • CrossRef
5. Fedele D, Comi G, Coscelli C, Cucinotta D, Feldman EL, Ghirlanda G, et al. A multicenter study on the prevalence of diabetic neuropathy in Italy. Diabetes Care. 1997;20:836–843
   • MEDLINE
6. Feldman EL, Stevens MJ, Thomas PK, Brown MB, Canal N, Greene DA. A practical two-step quantitative clinical and electrophysiological assessment for the diagnosis and staging of diabetic neuropathy. Diabetes Care. 1994;17:1281–1289
   • MEDLINE
7. Franklin GM, Kahn LB, Baxter J, Marshall JA, Hamman RF. Sensory neuropathy in non-insulin-dependent diabetes mellitus. The San Luis Valley diabetes study. American Journal of Epidemiology. 1990;131:633–643
   • MEDLINE
8. Franklin GM, Shetterly SM, Cohen JA, Baxter J, Hamman RF. Risk factors for distal symmetric neuropathy in NIDDM. The San Luis Valley diabetes study. Diabetes Care. 1994;17:1172–1177
   • MEDLINE
9. Harris M, Eastman R, Cowic C. Symptoms of sensory neuropathy in adults with NIDDM in the US population. Diabetes Care. 1993;16:1446–1452
   • MEDLINE
10. Kastenbauer T, Sauseng S, Sokol G, Auinger M, Irsigler K. A prospective study of predictors for foot ulceration in type 2 diabetes. Journal of the American Podiatric Medical Association. 2001;91:343–350
    • MEDLINE
11. Maser RE, Pfeifer MA, Dorman JS, Kuller LH, Becker DJ, Orchard TJ. Diabetic autonomic neuropathy and cardiovascular risk. Pittsburg epidemiology of diabetes complications Study III. Archives of Internal Medicine. 1990;150:1218–1222
    • MEDLINE
12. Proceedings of a consensus development conference on standardized measures in diabetic neuropathy (1992). Diabetes Care, 15, 1079-07.
13. Stevens MJ, Feldman EL, Greene DA. The aetiology of diabetic neuropathy: the combined roles of metabolic and vascular defects. Diabetic Medicine. 1995;12:566–579
14. Tesfaye S, Stevens LK, Stephenson JM, Fuller JH, Plater M, Ionescu TC, et al. Prevalence of diabetic peripheral neuropathy and its relation to glycaemic control and potential risk factors: the EURODIAB IDDM Complications Study. Diabetologia. 1996;39:1377–1384
    • MEDLINE
    • CrossRef
15. The Diabetes Control and Complications Trial Research Group. The effect of intensive diabetes therapy on the development and progression of neuropathy. Annals of Internal Medicine. 1995;122:561–568
    • MEDLINE
16. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837–853
    • Abstract
    • Full Text
    • Full-Text PDF (708 KB)
    • CrossRef
17. Young MJ, Breddy JL, Veves A, Boulton AJ. The prediction of diabetic neuropathic foot ulceration using vibration perception thresholds. A prospective study. Diabetes Care. 1994;17:557–560
    • MEDLINE